A biological characterization of patients with postmenopausal Parkinson's disease

Roberta Bovenzi,Tommaso Schirinzi,Matteo Conti,Giulia Maria Sancesario,Henri Zenuni,Clara Simonetta,Jacopo Bissacco,Davide Mascioli,Massimo Pieri,Rocco Cerroni,Alessandro Stefani,Nicola Biagio Mercuri,Mariangela Pierantozzi
DOI: https://doi.org/10.1007/s00415-024-12258-8
2024-03-17
Journal of Neurology
Abstract:Menopause increases the risk for Parkinson's disease (PD), although the underlying biological mechanisms have not been established in patients. Here, we aimed to understand the basis of menopause-related vulnerability to PD. Main motor and non-motor scores, blood levels of estradiol, testosterone, follicle-stimulating hormone, and luteinizing hormone, CSF levels of total α-synuclein, amyloid-β-42, amyloid-β-40, total tau, and phosphorylated-181-tau were examined in 45 women with postmenopausal-onset PD and 40 age-matched controls. PD patients had higher testosterone and lower estradiol levels than controls, and the residual estradiol production was associated with milder motor disturbances and lower dopaminergic requirements. In PD but not in controls, follicle-stimulating hormone levels correlated with worse cognitive scores and CSF markers of amyloidopathy and neuronal loss. In conclusion, menopause-related hormonal changes might differentially contribute to clinical-pathological trajectories of PD, accounting for the peculiar vulnerability to the disease.
clinical neurology
What problem does this paper attempt to address?